SCHEMBL22926076

SCHEMBL22926076

O=C(O)c1ncc(Nc2nc(-c3ccc(C(F)(F)F)cc3)co2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.51
▸ PPARA Q07869 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ TRPV1 Q8NER1 2/20 0.37
▸ KIF11 P52732 2/20 0.37
▸ ADORA3 P0DMS8 1/20 0.36
▸ KMO O15229 1/20 0.36
▸ MRGPRX4 Q96LA9 1/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ SNCA P37840 1/20 0.35
▸ GCGR P47871 1/20 0.35
▸ IKBKB O14920 1/20 0.35
▸ KCNQ3 O43525 1/20 0.35
▸ KCNQ2 O43526 1/20 0.35
▸ KCNE1 P15382 1/20 0.35
▸ KCNQ1 P51787 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ TSPO P30536 1/20 0.35
▸ P2RY14 Q15391 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22925676 0.89 HSD11B1 (0.47) HSD11B1TRPV1SNCAKCNQ3KCNQ2
SCHEMBL22926077 0.88 HSD11B1 (0.46) HSD11B1GSK3BTRPV1KIF11ADORA3
SCHEMBL22925878 0.86 HSD11B1 (0.49) HSD11B1TRPV1KIF11
SCHEMBL22926078 0.81 HSD11B1 (0.46) HSD11B1TRPV1MRGPRX4
SCHEMBL31013378 0.80 HSD11B1 (0.45) HSD11B1GSK3BTRPV1KCNQ3KCNQ2
SCHEMBL22925671 0.80 HSD11B1 (0.45) HSD11B1GSK3BTRPV1KCNQ3KCNQ2
SCHEMBL22925877 0.79 HSD11B1 (0.44) HSD11B1GSK3BTRPV1KIF11
SCHEMBL22925571 0.79 TRPV1 (0.49) GSK3BTRPV1
SCHEMBL22925865 0.77 HSD11B1 (0.51) HSD11B1GSK3BKIF11ADORA3P2RY14
SCHEMBL24636908 0.76 HSD11B1 (0.45) HSD11B1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 — — CN disclosed
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 — — US disclosed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 — — EP disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 — — CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB HSD11B1 843/4885PPARA 2438/4885GSK3B 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback